{"nctId":"NCT03092375","briefTitle":"Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects","startDateStruct":{"date":"2017-04-20","type":"ACTUAL"},"conditions":["Hepatitis C","HCV"],"count":177,"armGroups":[{"label":"Arm A: G/P 300 mg/120 mg QD for 12 Wks","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg"]},{"label":"Arm B: G/P 300 mg/120 mg QD for 16 Wks","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg"]},{"label":"Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg","Drug: Ribavirin 200Mg Tablet"]},{"label":"Arm D: G/P 300 mg/120 mg QD for 16 Wks","type":"EXPERIMENTAL","interventionNames":["Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg"]}],"interventions":[{"name":"Glecaprevir/Pibrentasvir (G/P) 300mg/120mg","otherNames":["Glecaprevir/Pibrentasvir","GLE/PIB (Glecaprevir/Pibrentasvir)"]},{"name":"Ribavirin 200Mg Tablet","otherNames":["Ribasphere 200Mg Tablet"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female at least 18 years of age at time of screening.\n2. A history of previous treatment with an NS5A-inhibitor plus sofosbuvir therapy ± RBV for chronic HCV genotype 1 infection.\n3. Treatment must have been completed at least 1 month prior to Screening Visit.\n4. Screening laboratory result indicating chronic HCV GT1 infection. Subjects must be able to understand and adhere to the study visit schedule and all other protocol requirements and must voluntarily sign and date an informed consent.\n\nExclusion Criteria:\n\n1. History of severe, life-threatening or other significant sensitivity to any drug.\n2. Female who is pregnant, planning to become pregnant during the study or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.\n3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.\n4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab) in patient without known history of HIV infection.\n5. HCV genotype performed during screening indicating co-infection with more than one HCV genotype.\n6. History or presence of liver decompensation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants","description":"Number of non-cirrhotic treatment-experienced HCV genotype 1 with a NS5Ai inhibitor + SOF +/-RBV participants with undetectable HCV RNA (HCV RNA \\<Lower Limit of Quantification -LLOQ) 12 weeks after completing G/P 300 mg/100 mg daily for 12 weeks (Arm A) vs. 16 weeks of G/P 300 mg/100 mg daily (Arm B)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Comparison of Cirrhotic Participants Achieving SVR 12 After G/P Plus RBV for 12 Wks vs. G/P for 16 Wks","description":"Number of cirrhotic participants who are treatment experienced with a NS5A inhibitor + SOF +/RBV with undetectable HCV RNA 12 weeks after completing G/P plus RBV for 12 wks vs. G/P for 16 Wks","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Tolerability of G/P +/-RBV","description":"Number of subjects who discontinued G/P due to adverse events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in On-Treatment Virologic Failure Between Arms A & B (Non-cirrhotic Subjects)","description":"Difference in % of subjects with on-treatment virologic failure further defined as either 1)Breakthrough a)Confirmed HCV RNA ≥ 100 IU/mL after HCV RNA \\< Lower Limit of Quantification (LLOQ) at some point during the Treatment Period or confirmed increase from nadir in HCV RNA (two consecutive measurements \\> 1 log10 IU/mL above nadir) at any time point during the Treatment Period, or b) a single value indicating viral breakthrough (≥ 100 IU/mL or \\> 1 log10 above nadir), followed by patient status of 'Lost to Follow-up', the latter not requiring confirmation by a proximate measurement) or 2) End of Treatment Failure defined as HCV RNA ≥ LLOQ at end of treatment and following at least 6 weeks of treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Relapse Between Arms A & B in Non-cirrhotic Subjects","description":"Difference in Post-treatment relapse (defined as confirmed HCV RNA\\>= Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after the last dose of study drug among subjects who completed treatment as planned with HCV RNA \\< LLOQ at end of treatment, excluding subjects with subjects with reinfection)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in On-Treatment Virologic Failure Between Arms C and D in Cirrhotic Subjects","description":"Difference in percentage of cirrhotic subjects experiencing on-treatment virologic failure (confirmed increase of \\> 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA \\< 15 IU/mL during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment) after 12 weeks of G/P with or without RBV for 12 weeks versus 16 weeks of G/P","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in % of Relapse Between Cirrhotic Arms C & D","description":"Difference in the percentage of compensated cirrhotic subjects with post-treatment relapse (defined as confirmed HCV RNA\\>=Lower limit of quantification (LLOQ) between end of treatment and 12 weeks after last dose of study drug among subjects who completed treatment as planned with HCV RNA\\<LLOQ at end of treatment) after receiving 12 weeks G/P +/-Ribavirin (RBV) (Arm C) versus 16 weeks G/P (Arm D)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in SVR12 Rates for 12-wk vs 16 wk","description":"Difference in proportions of SVR 12 rates will be determined for 12-week vs. 16-week treatment durations using contrasts within a logistic regression model with cirrhosis status and HCV genotype (1b vs non-1b) as factors","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":78},"commonTop":["Fatigue","Headache","Nausea","Arthralgia","Arthralgia"]}}}